Skip to main content
TipRanks
Go Ultimate75% OFF

SAB Biotherapeutics (SABS) Stock Statistics & Valuation Metrics

331 Followers

Total Valuation

SAB Biotherapeutics has a market cap or net worth of $265.76M. The enterprise value is $196.43M.

Market Cap
$265.76M
Enterprise Value
$196.43M

Share Statistics

SAB Biotherapeutics has 90,088,830 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
90,088,830
Owned by Insiders
9.88%
Owned by Institutions
75.27%

Financial Efficiency

SAB Biotherapeutics’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is -30.02%.

Return on Equity (ROE)
0.09
Return on Assets (ROA)
0.08
Return on Invested Capital (ROIC)
-30.02%
Return on Capital Employed (ROCE)
-0.30
Revenue Per Employee
0
Profits Per Employee
154.35K
Employee Count
86
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of SAB Biotherapeutics is -3.12. SAB Biotherapeutics’s PEG ratio is 0.02.

PE Ratio
-3.12
PS Ratio
0.00
PB Ratio
1.28
Price to FCF
-3.54
Price to Operating Cash Flow
-3.97
PEG Ratio
0.02

Income Statement

In the last 12 months, SAB Biotherapeutics had revenue of 0 and earned 13.27M in profits. Earnings per share was 0.22.

Revenue
0
Gross Profit
-3.08M
Operating Income
-48.95M
Pretax Income
13.27M
Net Income
13.27M
EBITDA
16.60M
Earnings Per Share (EPS)
0.22

Cash Flow

In the last 12 months, operating cash flow was -68.18M and capital expenditures -5.83M, giving a free cash flow of -74.01M billion.

Operating Cash Flow
-68.18M
Free Cash Flow
-74.01M
Free Cash Flow per Share
-0.79

Dividends & Yields

SAB Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-27.85%
Earnings Yield
-29.27%

Stock Price Statistics

Beta
1.28
52-Week Price Change
-15.71%
50-Day Moving Average
3.12
200-Day Moving Average
3.62
Relative Strength Index (RSI)
45.90
Average Volume (3m)
596.36K

Important Dates

SAB Biotherapeutics upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 05, 2026
Next Earnings Date
Apr 01, 2027
Ex-Dividend Date
―

Financial Position

SAB Biotherapeutics as a current ratio of 9.46, with Debt / Equity ratio of 3.93%

Current Ratio
9.46
Quick Ratio
9.46
Debt to Market Cap
0.01
Net Debt to EBITDA
-0.27
Interest Coverage Ratio
-203.41

Taxes

In the past 12 months, SAB Biotherapeutics has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

SAB Biotherapeutics EV to EBITDA ratio is -3.17, with an EV/FCF ratio of -3.46.

EV to Sales
0.00
EV to EBITDA
-3.17
EV to Free Cash Flow
-3.46
EV to Operating Cash Flow
-3.76

Balance Sheet

SAB Biotherapeutics has $104.05M in cash and marketable securities with $4.92M in debt, giving a net cash position of $99.13M billion.

Cash & Marketable Securities
$104.05M
Total Debt
$4.92M
Net Cash
$99.13M
Net Cash Per Share
$1.10
Tangible Book Value Per Share
$2.26

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for SAB Biotherapeutics is $13.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
$13.25
Price Target Upside
349.15% Upside
Analyst Consensus
Strong Buy
Analyst Count
4
Revenue Growth Forecast
-100.00%
EPS Growth Forecast
60.70%

Scores

Smart Score
7
AI Score
47